Navigation Links
Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
Date:9/29/2011

SAN DIEGO, Sept. 29, 2011 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced multiple Contrave® (naltrexone sustained release (SR)/bupropion SR) abstracts accepted for poster presentations and an oral presentation at the upcoming 29th Annual Scientific Meeting of The Obesity Society. This meeting will be held October 1-5, 2011 in Orlando, FL at the Orlando World Center Marriott.

Details on the presentation times are as follows:Monday, October 3, 2011 – Abstract #598-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Robert Chilton, DO; University of Texas Health Science Center, San Antonio, TX, USA.Title: Naltrexone SR/Bupropion SR Combination Therapy Improves Predicted 10-Year Risk of Cardiovascular Disease, Coronary Heart Disease, Myocardial Infarction, and Congestive Heart FailureMonday, October 3, 2011 – Abstract #605-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Ken Fujioka, MD; Scripps Clinic, La Jolla, CA, USA.Title: Completion of 56 Weeks of Naltrexone SR/Bupropion SR Combination Therapy Increases Likelihood of Achieving Improvements in Markers of Cardiometabolic Risk Associated with Clinically Meaningful Weight LossMonday, October 3, 2011 – Abstract #607-P, Presentation time 12:30-1:30PM EDT, Cypress BallroomPresenter: Patrick O'Neil, PhD; Medical University of South Carolina, Charleston, SC, USA.Title: Naltrexone SR/Bupropion SR and Intensive Behavioral Modification Combination Increases the Likelihood of Achieving Early and Sustained Weight Loss and Associated Improvement in Markers of Cardiometabolic RiskMonday, October 3, 2011 – Abstract #49-OR, Presentation time 3:15-4:45PM EDT, "Intervention and Clinical Studies - Surgery/Drugs" SessionPresenter: Gene-Jack Wang, MD; Brookhaven National Laboratory, Upton, NY Title: Reduced responses to food cue after combined therapy with naltrexone and bupropionAbout ContraveContrave, an investigational combination therapy of naltrexone HCl and bupropion HCl, was studied for its ability to help people with obesity initiate and sustain weight loss of at least 5 percent of their starting body weight in one year. Contrave was submitted for U.S. regulatory approval in March 2010. The original submission was based on multiple clinical trials that evaluated Contrave in more than 4500 patients. Orexigen received a Complete Response letter from FDA on January 31, 2011.

About Orexigen TherapeuticsOrexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave has completed Phase 3 clinical trials, and the Company's other product candidate, Empatic(TM), has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.


'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
2. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
3. Orexigen® Therapeutics Announces Corporate Realignment
4. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
5. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
6. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
7. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
8. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
9. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
10. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
11. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
Breaking Biology News(10 mins):